Page 128 - 《中国药房》2021年10期

hibitor GS-9669 against HCV genotype 1 infection[J]. genotype-1 HCV infection and cirrhosis：results from two
Gastroenterology，2014，146（3）：736-743. phase Ⅱ studies[J]. Antivir Ther，2016，21（8）：679-687.
[27] GANE E，POORDAD F，WANG S，et al. High efficacy of [38] LAWITZ E，GANE E，PEARLMAN B，et al. Efficacy and
ABT-493 and ABT-530 treatment in patients with HCV safety of 12 weeks versus 18 weeks of treatment with
genotype 1 or 3 infection and compensated cirrhosis[J]. grazoprevir（MK-5172）and elbasvir（MK-8742）with or
Gastroenterology，2016，151（4）：651-659. without ribavirin for hepatitis C virus genotype 1 infec-
[28] GEORGE J，BURNEVICH E，SHEEN I S，et al. Elbasvir/ tion in previously untreated patients with cirrhosis and pa-
grazoprevir in Asia-Pacific/Russian participants with chro- tients with previous null response with or without cirrhosis
nic hepatitis C virus genotype 1，4，or 6 infection[J]. Hepa- （C-WORTHY）：a randomised，open-label phase 2 trial[J].
tol Commun，2018，2（5）：595-606. Lancet，2015，385（9973）：1075-1086.
[29] IZUMI N，TAKEHARA T，CHAYAMA K，et al. Sofosbu- [39] LAWITZ E，POORDAD F F，PANG P S，et al. Sofosbuvir
vir-velpatasvir plus ribavirin in Japanese patients with ge- and ledipasvir fixed-dose combination with and without
notype 1 or 2 hepatitis C who failed direct-acting antivi- ribavirin in treatment-naive and previously treated pa-
rals[J]. Hepatol Int，2018，12（4）：356-367. tients with genotype 1 hepatitis C virus infection（LONE-
[30] KAO J H，TUNG S Y，LEE Y，et al. Ritonavir-boosted STAR）：an open-label，randomised，phase 2 trial[J]. Lan-
danoprevir plus peginterferon alfa-2a and ribavirin in cet，2014，383（9916）：515-523.
Asian chronic hepatitis C patients with or without cirrho- [40] MANNS M，SAMUEL D，GANE E J，et al. Ledipasvir
sis[J]. J Gastroenterol Hepatol，2016，31（10）：1757-1765. and sofosbuvir plus ribavirin in patients with genotype 1
[31] KAWAKAMI Y，OCHI H，HAYES C N，et al. Efficacy or 4 hepatitis C virus infection and advanced liver di-
and safety of ledipasvir/sofosbuvir with ribavirin in chro- sease：a multicentre，open-label，randomised，phase 2 trial
nic hepatitis C patients who failed daclatasvir/asunaprevir [J]. Lancet Infect Dis，2016，16（6）：685-697.
therapy：pilot study[J]. J Gastroenterol，2018，53（4）：548- [41] MARCELLIN P，COOPER C，BALART L，et al. Rando-
556. mized controlled trial of danoprevir plus peginterferon
[32] KOWDLEY K V，GORDON S C，REDDY K R，et al. Le- alfa2a and ribavirin in treatment-naïve patients with
dipasvir and sofosbuvir for 8 or 12 weeks for chronic hepatitis C virus genotype 1 infection[J]. Gastroenterology，
HCV without cirrhosis[J]. N Engl J Med，2014，370（20）： 2013，145（4）：790-800.
1879-1888. [42] MIZOKAMI M，YOKOSUKA O，TAKEHARA T，et al.
[33] KOWDLEY K V，LAWITZ E，POORDAD F，et al. Phase Ledipasvir and sofosbuvir fixed-dose combination with
2b trial of interferon-free therapy for hepatitis C virus ge- and without ribavirin for 12 weeks in treatment-naive and
notype 1[J]. N Engl J Med，2014，370（3）：222-232. previously treated Japanese patients with genotype 1 he-
[34] KUMADA H，SUZUKI Y，KARINO Y，et al. The combi- patitis C：an open-label，randomised，phase 3 trial[J]. Lan-
nation of elbasvir and grazoprevir for the treatment of cet Infect Dis，2015，15（6）：645-653.
chronic HCV infection in Japanese patients：a randomized [43] NGUYEN E，TRINH S，TRINH H，et al. Sustained viro-
phase Ⅱ/Ⅲ study[J]. J Gastroenterol，2017，52（4）：520- logic response rates in patients with chronic hepatitis C
533. genotype 6 treated with ledipasvir+sofosbuvir or sofosbu-
[35] KWO P，GANE E J，PENG C Y，et al. Effectiveness of El- vir+velpatasvir[J]. Aliment Pharmacol Ther，2019，49（1）：
basvir and grazoprevir combination，with or without riba- 99-106.
virin，for treatment-experienced patients with chronic he- [44] PIANKO S，FLAMM S L，SHIFFMAN M L，et al. Sofos-
patitis C infection[J]. Gastroenterology，2017，152（1）： buvir plus velpatasvir combination therapy for treat-
164-175. ment-experienced patients with genotype 1 or 3 hepatitis
[36] LAWITZ E，POORDAD F，GUTIERREZ J A，et al.Short- C virus infection：a randomized trial[J]. Ann Intern Med，
duration treatment with elbasvir/grazoprevir and sofosbu- 2015，163（11）：809-817.
vir for hepatitis C：a randomized trial[J]. Hepatology， [45] POORDAD F，FELIZARTA F，ASATRYAN A，et al. Gle-
2017，65（2）：439-450. caprevir and pibrentasvir for 12 weeks for hepatitis C vi-
[37] LAWITZ E，POORDAD F，HYLAND R H，et al. Ledipas- rus genotype 1 infection and prior direct-acting antiviral
vir/sofosbuvir-based treatment of patients with chronic treatment[J]. Hepatology，2017，66（2）：389-397.

·1270 · China Pharmacy 2021 Vol. 32 No. 10 中国药房 2021年第32卷第10期